Investigations on CXCL13 in Anti–<i>N</i>-Methyl-<scp>D</scp>-Aspartate Receptor Encephalitis

Abstract

Seventy percent of patients with early-stage anti-NMDAR encephalitis had increased CSF CXCL13 concentration that correlated with intrathecal NMDAR-antibody synthesis. Prolonged or secondary elevation of CXCL13 was associated with limited response to treatment and relapses. CXCL13 is a potentially useful biomarker of treatment response and outcome in anti-NMDAR encephalitis.